Cognition enhancing effect in albino Swiss CD-1 mouse assessed as reversal of scopolamine-induced amnesia at 20 to 30 mg/kg, ip treated 30 mins prior to acquisition trial followed by scopolamine challenge immediately after acquisition trial by passive avoidance test (Rvb = 39.31 +/- 4.01 secs)
Antagonist activity at human H3 receptor expressed in HEK293 cells assessed as inhibition of RAMH-induced reduction of forskolin-stimulated cAMP accumulation after 30 mins by Ulight-based TR-FRET assay
In vivo antagonist activity at H3 receptor in RAMH-induced dipsogenic ip dosed Wistar (Krf:(WI) WU) rat model assessed as inhibition of RAMH-water intake administered 30 mins prior to RAMH induction
Neurotoxicity in albino CF-1 mouse assessed as increase in subcutaneous pentylenetetrazole-induced continuous seizures at 50 mg/kg, ip measured after 0.25 hrs
Neurotoxicity in albino CF-1 mouse assessed as increase in subcutaneous pentylenetetrazole-induced continuous seizures at 50 mg/kg, ip measured after 0.5 hrs
Neurotoxicity in albino CF-1 mouse assessed as increase in subcutaneous pentylenetetrazole-induced continuous seizures at 50 mg/kg, ip measured after 1 hr
Neurotoxicity in albino CF-1 mouse assessed as increase in subcutaneous pentylenetetrazole-induced continuous seizures at 50 mg/kg, ip measured after 2 hrs
Anticonvulsant activity in albino CF-1 mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 50 mg/kg, ip measured after 4 hrs